Gri bio presents positive preclinical data demonstrating lead program gri-0621 reduces the important inflammatory and fibrotic drivers in idiopathic pulmonary fibrosis (ipf)

Compared to controls, mice treated with gri-0621 showed improved fibrosis and immunopathology; inhibition of type 1 invariant natural killer t (inkt) cell activity led to a decrease in fibrosis score and total lung inflammation

GRI Ratings Summary

GRI Quant Ranking